FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3105125497> ?p ?o ?g. }

• W3105125497 abstract "Background Despite clinical successes of immune checkpoint blockade (ICB) antibodies blocking the inhibitory receptors CTLA-4, PD-1, or PD-L1, substantial challenges remain. Many patients do not respond, and ICB treatment is associated with serious immune-related adverse effects (irAEs) which are exacerbated by combination therapies. TIGIT blockade has been demonstrated to provide tumor control in pre-clinical studies, sparking ongoing clinical trials, including those targeting TIGIT in combination with anti-PD-1 or anti-PD-L1. The INTASYL™ platform is a self-delivering RNAi technology that (1) provides efficient delivery into target cells bypassing the need for specialized formulations, mechanical perturbation, or drug delivery systems; and (2) specifically and durably silence target gene expression when administered intratumorally (IT), providing in vivo tumor control. IT administration restricts pharmacokinetics to the tumor; an attractive strategy for mitigating ICB-mediated systemic irAEs. Additionally, using INTASYL, multiple targets can be silenced in combination. Here we demonstrate the in vivo efficacy of INTASYL specifically targeting TIGIT (PH-804), PD-1 (PH-762), PD-L1 (PH-790) alone or in combination in a CT26 model of murine colorectal carcinoma. Methods To assess silencing activity, activated human pan-T cells were incubated in vitro with INTASYL compounds either alone or in combination and mRNA silencing was determined by qRT-PCR and protein silencing by flow cytometry. To assess in vivo tumor efficacy CT-26 cells were implanted subcutaneously into BALB/c mice. INTASYL compounds were administered IT at 1 mg/dose on Days 1, 3, 7, and 10 either as single agents (mPH-804, mPH-762, mPH-790) or in combination (mPH-804 + mPH-762 or mPH-804 + mPH-790). Controls consisted of PBS (vehicle; (IT)), and anti-TIGIT, anti-PD-1, or anti-PD-L1 antibodies (0.2 mg/dose) administered via intraperitoneal injection (IP). Tumor volumes and body weight were recorded throughout the study. Tumors were taken at the end of the study for analysis. Results Single and combination knockdown of target molecules was validated at the mRNA level (=90%) by qRT-PCR and at the protein level (=80%) in activated human pan-T cells. In vivo, combination treatment with mPH-804 + mPH-762 or mPH-790 improved tumor control compared to individual monotherapies providing evidence of potential synergy. All treatments were well tolerated. Conclusions n/a Acknowledgements We demonstrate the potential of INTASYL-mediated combination therapy targeting TIGIT and PD-1/PD-L1. These findings indicate that combination of TIGIT + PD-1/PD-L1 silencing improves tumor control compared to monotherapy. As INTASYL IT is efficacious and may mitigate irAEs caused by antibody ICB, INTASYL combination therapies including PH-804, PH-762 and PH-790 warrant further investigation in patients." @default.
• W3105125497 created "2020-11-23" @default.
• W3105125497 creator A5024915505 @default.
• W3105125497 creator A5030738623 @default.
• W3105125497 creator A5057916077 @default.
• W3105125497 creator A5067022917 @default.
• W3105125497 creator A5081951424 @default.
• W3105125497 creator A5083071027 @default.
• W3105125497 date "2020-11-01" @default.
• W3105125497 modified "2023-09-23" @default.
• W3105125497 title "198 Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer" @default.
• W3105125497 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0198" @default.
• W3105125497 hasPublicationYear "2020" @default.
• W3105125497 type Work @default.
• W3105125497 sameAs 3105125497 @default.
• W3105125497 citedByCount "0" @default.
• W3105125497 crossrefType "journal-article" @default.
• W3105125497 hasAuthorship W3105125497A5024915505 @default.
• W3105125497 hasAuthorship W3105125497A5030738623 @default.
• W3105125497 hasAuthorship W3105125497A5057916077 @default.
• W3105125497 hasAuthorship W3105125497A5067022917 @default.
• W3105125497 hasAuthorship W3105125497A5081951424 @default.
• W3105125497 hasAuthorship W3105125497A5083071027 @default.
• W3105125497 hasBestOaLocation W31051254971 @default.
• W3105125497 hasConcept C104317684 @default.
• W3105125497 hasConcept C119056186 @default.
• W3105125497 hasConcept C121608353 @default.
• W3105125497 hasConcept C126322002 @default.
• W3105125497 hasConcept C150903083 @default.
• W3105125497 hasConcept C185592680 @default.
• W3105125497 hasConcept C203014093 @default.
• W3105125497 hasConcept C207001950 @default.
• W3105125497 hasConcept C2776999253 @default.
• W3105125497 hasConcept C2777701055 @default.
• W3105125497 hasConcept C2779118045 @default.
• W3105125497 hasConcept C2781053074 @default.
• W3105125497 hasConcept C502942594 @default.
• W3105125497 hasConcept C526805850 @default.
• W3105125497 hasConcept C55493867 @default.
• W3105125497 hasConcept C71924100 @default.
• W3105125497 hasConcept C86803240 @default.
• W3105125497 hasConcept C8891405 @default.
• W3105125497 hasConcept C98274493 @default.
• W3105125497 hasConceptScore W3105125497C104317684 @default.
• W3105125497 hasConceptScore W3105125497C119056186 @default.
• W3105125497 hasConceptScore W3105125497C121608353 @default.
• W3105125497 hasConceptScore W3105125497C126322002 @default.
• W3105125497 hasConceptScore W3105125497C150903083 @default.
• W3105125497 hasConceptScore W3105125497C185592680 @default.
• W3105125497 hasConceptScore W3105125497C203014093 @default.
• W3105125497 hasConceptScore W3105125497C207001950 @default.
• W3105125497 hasConceptScore W3105125497C2776999253 @default.
• W3105125497 hasConceptScore W3105125497C2777701055 @default.
• W3105125497 hasConceptScore W3105125497C2779118045 @default.
• W3105125497 hasConceptScore W3105125497C2781053074 @default.
• W3105125497 hasConceptScore W3105125497C502942594 @default.
• W3105125497 hasConceptScore W3105125497C526805850 @default.
• W3105125497 hasConceptScore W3105125497C55493867 @default.
• W3105125497 hasConceptScore W3105125497C71924100 @default.
• W3105125497 hasConceptScore W3105125497C86803240 @default.
• W3105125497 hasConceptScore W3105125497C8891405 @default.
• W3105125497 hasConceptScore W3105125497C98274493 @default.
• W3105125497 hasLocation W31051254971 @default.
• W3105125497 hasOpenAccess W3105125497 @default.
• W3105125497 hasPrimaryLocation W31051254971 @default.
• W3105125497 hasRelatedWork W10598216 @default.
• W3105125497 hasRelatedWork W14333088 @default.
• W3105125497 hasRelatedWork W2431775 @default.
• W3105125497 hasRelatedWork W3224415 @default.
• W3105125497 hasRelatedWork W4281585 @default.
• W3105125497 hasRelatedWork W5673875 @default.
• W3105125497 hasRelatedWork W6349928 @default.
• W3105125497 hasRelatedWork W6449941 @default.
• W3105125497 hasRelatedWork W7355637 @default.
• W3105125497 hasRelatedWork W9714991 @default.
• W3105125497 isParatext "false" @default.
• W3105125497 isRetracted "false" @default.
• W3105125497 magId "3105125497" @default.
• W3105125497 workType "article" @default.